Literature DB >> 24218367

Comparative receptor tyrosine kinase profiling identifies a novel role for AXL in human stem cell pluripotency.

Mi-Young Son1, Binna Seol, Yong-Mahn Han, Yee Sook Cho.   

Abstract

The extensive molecular characterization of human pluripotent stem cells (hPSCs), human embryonic stem cells (hESCs) and human-induced pluripotent stem cells (hiPSCs) is required before they can be applied in the future for personalized medicine and drug discovery. Despite the efforts that have been made with kinome analyses, we still lack in-depth insights into the molecular signatures of receptor tyrosine kinases (RTKs) that are related to pluripotency. Here, we present the first detailed and distinct repertoire of RTK characteristic for hPSC pluripotency by determining both the expression and phosphorylation profiles of RTKs in hESCs and hiPSCs using reverse transcriptase-polymerase chain reaction with degenerate primers that target conserved tyrosine kinase domains and phospho-RTK array, respectively. Among the RTKs tested, the up-regulation of EPHA1, ERBB2, FGFR4 and VEGFR2 and the down-regulation of AXL, EPHA4, PDGFRB and TYRO3 in terms of both their expression and phosphorylation levels were predominantly related to the maintenance of hPSC pluripotency. Notably, the specific inhibition of AXL was significantly advantageous in maintaining undifferentiated hESCs and hiPSCs and for the overall efficiency and kinetics of hiPSC generation. Additionally, a global phosphoproteomic analysis showed that ∼30% of the proteins (293 of 970 phosphoproteins) showed differential phosphorylation upon AXL inhibition in undifferentiated hPSCs, revealing the potential contribution of AXL-mediated phosphorylation dynamics to pluripotency-related signaling networks. Our findings provide a novel molecular signature of AXL in pluripotency control that will complement existing pluripotency-kinome networks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24218367     DOI: 10.1093/hmg/ddt571

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  6 in total

Review 1.  Protein kinases and associated pathways in pluripotent state and lineage differentiation.

Authors:  Melina Shoni; Kathy O Lui; Demetrios G Vavvas; Michael G Muto; Ross S Berkowitz; Nikolaos Vlahos; Shu-Wing Ng
Journal:  Curr Stem Cell Res Ther       Date:  2014       Impact factor: 3.828

2.  High-dose folic acid supplementation alters the human sperm methylome and is influenced by the MTHFR C677T polymorphism.

Authors:  Mahmoud Aarabi; Maria C San Gabriel; Donovan Chan; Nathalie A Behan; Maxime Caron; Tomi Pastinen; Guillaume Bourque; Amanda J MacFarlane; Armand Zini; Jacquetta Trasler
Journal:  Hum Mol Genet       Date:  2015-08-24       Impact factor: 6.150

3.  Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease.

Authors:  Mi-Young Son; Mi-Ok Lee; Hyejin Jeon; Binna Seol; Jung Hwa Kim; Jae-Suk Chang; Yee Sook Cho
Journal:  Exp Mol Med       Date:  2016-05-13       Impact factor: 8.718

4.  In Silico Designed Axl Receptor Blocking Drug Candidates Against Zika Virus Infection.

Authors:  Edita Sarukhanyan; Sergey Shityakov; Thomas Dandekar
Journal:  ACS Omega       Date:  2018-05-16

5.  A liver-specific gene expression panel predicts the differentiation status of in vitro hepatocyte models.

Authors:  Dae-Soo Kim; Jea-Woon Ryu; Mi-Young Son; Jung-Hwa Oh; Kyung-Sook Chung; Sugi Lee; Jeong-Ju Lee; Jun-Ho Ahn; Ju-Sik Min; Jiwon Ahn; Hyun Mi Kang; Janghwan Kim; Cho-Rok Jung; Nam-Soon Kim; Hyun-Soo Cho
Journal:  Hepatology       Date:  2017-10-03       Impact factor: 17.425

6.  Histone modifications and p53 binding poise the p21 promoter for activation in human embryonic stem cells.

Authors:  Yoko Itahana; Jinqiu Zhang; Jonathan Göke; Leah A Vardy; Rachel Han; Kozue Iwamoto; Engin Cukuroglu; Paul Robson; Mahmoud A Pouladi; Alan Colman; Koji Itahana
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.